Loxo Oncology, Inc. (NASDAQ:LOXO) VP Jennifer Burstein sold 1,500 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $87.50, for a total transaction of $131,250.00. Following the completion of the transaction, the vice president now directly owns 1,500 shares in the company, valued at approximately $131,250. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jennifer Burstein also recently made the following trade(s):

  • On Thursday, December 14th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $83.27, for a total transaction of $141,559.00.
  • On Monday, November 27th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $74.82, for a total transaction of $127,194.00.
  • On Monday, October 30th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $87.19, for a total transaction of $148,223.00.

Loxo Oncology, Inc. (NASDAQ LOXO) traded up $1.40 during trading on Thursday, hitting $90.47. 433,863 shares of the stock traded hands, compared to its average volume of 319,425. The stock has a market capitalization of $2,720.00, a P/E ratio of -15.57 and a beta of 2.54. Loxo Oncology, Inc. has a 1-year low of $36.75 and a 1-year high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.26. equities research analysts forecast that Loxo Oncology, Inc. will post -5.91 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new position in Loxo Oncology during the third quarter valued at approximately $122,000. Ameritas Investment Partners Inc. grew its position in Loxo Oncology by 31.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 419 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Loxo Oncology by 4,388.0% during the second quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,194 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Loxo Oncology during the third quarter valued at approximately $212,000. Finally, Amalgamated Bank purchased a new position in Loxo Oncology during the third quarter valued at approximately $268,000. 99.98% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. William Blair assumed coverage on shares of Loxo Oncology in a research report on Tuesday, November 28th. They issued an “outperform” rating on the stock. Citigroup dropped their target price on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 16th. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Cowen reissued a “buy” rating on shares of Loxo Oncology in a research report on Thursday, September 28th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Loxo Oncology presently has a consensus rating of “Buy” and a consensus target price of $90.57.

ILLEGAL ACTIVITY WARNING: “Loxo Oncology, Inc. (LOXO) VP Jennifer Burstein Sells 1,500 Shares” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/18/loxo-oncology-inc-loxo-vp-jennifer-burstein-sells-1500-shares.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.